WASHINGTON – In a decision with important implications for the evolving field of personalized medicine, a unanimous U.S. Supreme Court on March 20 invalidated two patents on a diagnostic test used in connection with the treatment of autoimmune diseases.

Mayo Collaborative Services v. Prometheus Laboratories Inc., 10-1150, pitted doctors and researchers against biotechnology and pharmaceutical companies in the ongoing debate over what is patentable subject matter.